Besides the infusion of ex vivo DC primed with autologous tumor lysates (DCvax-L), the infusion of combinations of cells and lysates of autologous and allogeneic glioma cells (Sitoiganap) can also be used to stimulate a robust, polyclonal CD8+ T cell response capable of mediating tumor regression. Here, CD8A is linked to glioma.